REGENXBIO Inc. (NASDAQ:RGNX) Stock Has Consensus Target Price of $23.18 According to Analysts

Key Points

• Analysts give REGENXBIO a consensus “Moderate Buy” rating, with an average 12-month price target of $23.18; 8 of 13 analysts rate it Buy and 1 Strong Buy.
• The stock opened at $8.47 and has traded between $5.45 and $16.19 over the past 52 weeks.
• REGENXBIO reported a quarterly loss of $0.62 per share, better than analysts’ expected loss of $1.29, while revenue of $9.16 million fell short of the $10.89 million estimate.

REGENXBIO Inc. (NASDAQ:RGNX - Get Free Report) has been given an average rating of "Moderate Buy" by the thirteen ratings firms that are currently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, three have given a hold recommendation, eight have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month price target among brokerages that have covered the stock in the last year is $23.18.

A number of brokerages recently weighed in on RGNX. Zacks Research raised shares of REGENXBIO from a "strong sell" rating to a "hold" rating in a research note on Wednesday, August 12th. Morgan Stanley reaffirmed an "overweight" rating and set a $18.00 price target on shares of REGENXBIO in a research report on Friday, August 7th. UBS Group reiterated a "positive" rating on shares of REGENXBIO in a report on Friday, November 6th. Weiss Ratings upgraded REGENXBIO from a "sell (e+)" rating to a "sell (d-)" rating in a report on Monday. Finally, HC Wainwright reissued a "buy" rating on shares of REGENXBIO in a research report on Monday, September 28th.

REGENXBIO Stock Performance

REGENXBIO stock opened at $8.47 on Thursday. The firm has a market cap of $560.04 million, a price-to-earnings ratio of -2.64 and a beta of 1.24. REGENXBIO has a 52-week low of $5.45 and a 52-week high of $16.19. The firm has a 50 day moving average price of $7.72 and a two-hundred day moving average price of $8.96.

REGENXBIO (NASDAQ:RGNX - Get Free Report) last posted its quarterly earnings data on Thursday, November 5th. The biotechnology company reported ($0.62) EPS for the quarter, beating analysts' consensus estimates of ($1.29) by $0.67. REGENXBIO had a negative net margin of 113.85% and a negative return on equity of 203.98%. The company had revenue of $9.16 million for the quarter, compared to analyst estimates of $10.89 million. As a group, equities research analysts predict that REGENXBIO will post -3.01 EPS for the current fiscal year.

Recent REGENXBIO Headlines

Here are a few of the latest headlines about RGNX:

• Positive Sentiment: HC Wainwright improved its FY2026 EPS estimate to a loss of $3.15 per share from a projected loss of $3.65. REGENXBIO analyst estimates
• Neutral Sentiment: A report listed REGENXBIO short interest at zero shares, providing no clear indication of meaningful short positioning; the accompanying claim of a significant increase conflicts with that figure.
• Negative Sentiment: HC Wainwright cut its EPS estimates for Q4 2026 and each quarter of 2027, and lowered its FY2027 estimate to a loss of $4.41 per share from $4.02. The repeated revisions point to expectations of larger losses and may pressure the stock. The firm nevertheless kept its Buy rating. REGENXBIO analyst estimates

Institutional Investors Weigh In On REGENXBIO

Several large investors have recently added to or reduced their stakes in the business. Mirae Asset Global Investments Co. Ltd. bought a new stake in REGENXBIO in the third quarter worth approximately $25,000. Versant Capital Management Inc boosted its holdings in shares of REGENXBIO by 60.4% during the 2nd quarter. Versant Capital Management Inc now owns 2,741 shares of the biotechnology company's stock worth $33,000 after buying an additional 1,032 shares in the last quarter. Quantbot Technologies LP bought a new position in shares of REGENXBIO during the 2nd quarter worth approximately $51,000. Legal & General Group Plc bought a new position in shares of REGENXBIO during the 2nd quarter worth approximately $56,000. Finally, StoneX Group Inc. acquired a new stake in shares of REGENXBIO during the 3rd quarter worth approximately $81,000. Institutional investors and hedge funds own 88.08% of the company's stock.

REGENXBIO Company Profile

REGENXBIO Inc. is a biotechnology company focused on developing gene therapies for inherited diseases and other serious conditions. Founded in 2008 and headquartered in Rockville, Maryland, the company uses its proprietary NAV AAV gene-delivery platform to develop treatments intended to deliver genetic material to patients' cells. Its research programs have included RGX-314, an investigational gene therapy for retinal diseases such as wet age-related macular degeneration, and candidates for conditions including Hunter syndrome and Duchenne muscular dystrophy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.